启迪药业集团股份公司 二、信息披露义务人签署本报告书已获得必要的授权和批准，其行为亦不 违反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 详式权益变动报告书 上市公司名称：启迪药业集团股份公司 股票上市地点：深圳证券交易所 股票简称：启迪药业 股票代码：000590.SZ 信息披露义务人：湖南赛乐仙管理咨询服务合伙企业（有限合伙） 注册地址：长沙市开福区青竹湖街道青竹湖路 29 号长沙金霞海关保税物流 投资建设有限公司商务写字楼 1607 房 通讯地址：长沙市开福区青竹湖街道青竹湖路 29 号长沙金霞海关保税物流 投资建设有限公司商务写字楼 1607 房 股份变动性质：股份增加（司法拍卖） 签署日期：2025 年 8 月 启迪药业集团股份有限公司详式权益变动报告书 信息披露义务人声明 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》及相关法律、法规和部门规章有关规定编制。 | 第一节 | 释 义 3 | ...

启迪药业集团股份公司 关于控股股东所持公司股份被司法拍卖暨控制权拟发生变更的 证券代码：000590 证券简称：启迪药业 公告编号：2025-026 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、2025 年 8 月 6 日，启迪药业集团股份公司（以下简称"公司"或"启 迪药业"）收到湖南赛乐仙管理咨询服务合伙企业（有限合伙）（以下简称 "湖南赛乐仙"）送达的北京金融法院《执行裁定书》【(2024)京 74 执 1019 号】，裁定将被执行人启迪科技服务有限公司（以下简称"启迪科服"）持有 的启迪药业 58,606,962 股股票过户至买受人湖南赛乐仙名下，买受人可持裁定 书到相关登记管理机构办理过户登记手续。 2、本次权益变动系公司控股股东启迪科服所持有的公司 58,606,962 股股票 被司法拍卖所致。本次权益变动后，启迪科服将不再持有公司股票，启迪科服及 其一致行动人北京华清投资有限公司（以下简称"华清投资"）持有的公司股票 总数从 63,151,413 股下降为 4,544,451 股，占公司总股本的比例从 26.3 ...

中信证券股份有限公司 关于 启迪药业集团股份公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年八月 中信证券股份有限公司关于启迪药业集团股份有限公司详式权益变动报告书之财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》及《公开发行证券的公司信息披露内容与格式准则第16号——上市公司 收购报告书》等法律法规和规范性文件的规定，中信证券股份有限公司（以下简 称"本财务顾问"）按照行业公认的业务标准、道德规范，本着诚实信用、勤勉 尽责的精神，对本次权益变动的相关情况和资料进行了核查，对信息披露义务人 出具的《启迪药业集团股份有限公司详式权益变动报告书》所披露的内容出具核 查意见，以供投资者和有关各方参考。 为此，本财务顾问特作出以下声明： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《启迪药业集团股份有限公司详式权益变动报告书》进行了核查，确信披露文件 内容与格式符合规定，并有充分理由确信所发表的专业意见与信息披露义务人披 露的文件内容不存在实质性差 ...

Market Overview - The Shanghai Composite Index closed at 3602.13 points, with a gain of 0.53% [1] - The total trading volume of A-shares reached 10185.93 billion yuan [1] Technical Analysis - A total of 29 A-shares experienced a death cross between the 5-day and 10-day moving averages today [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xiongdi Technology: 5-day MA down by 1.70% from the 10-day MA [1] - Sanwei Xinan: 5-day MA down by 1.11% from the 10-day MA [1] - Jinling Sports: 5-day MA down by 1.10% from the 10-day MA [1] Individual Stock Performance - Xiongdi Technology (300546): Today's change -0.23%, latest price 26.47 yuan, 5-day MA 27.31 yuan, 10-day MA 27.78 yuan [1] - Sanwei Xinan (688489): Today's change -0.80%, latest price 39.85 yuan, 5-day MA 40.62 yuan, 10-day MA 41.08 yuan [1] - Jinling Sports (300651): Today's change +0.89%, latest price 21.48 yuan, 5-day MA 23.82 yuan, 10-day MA 24.09 yuan [1] - Other notable stocks include: - Huanrui Century (000892): Today's change -0.86%, latest price 4.59 yuan [1] - Junshi Biological (688180): Today's change +0.45%, latest price 37.83 yuan [1] - Yihau New Materials (301176): Today's change -1.64%, latest price 30.65 yuan [1] Additional Stock Data - Other stocks with notable performance include: - Guanghe Technology (001389): Today's change -2.81%, latest price 62.20 yuan [1] - Kehua Data (002335): Today's change -2.13%, latest price 41.44 yuan [1] - ST Ruihe (002620): Today's change +0.26%, latest price 3.84 yuan [1] - The performance of these stocks indicates a mixed sentiment in the market, with some stocks showing declines while others remain stable or increase slightly [1][2]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The Chinese medicine sector saw a 3.12% increase last week, with the overall pharmaceutical sector rising by 2.95% [2] - The PE (ttm) for the Chinese medicine sector is 29.58X, up 0.89X week-on-week, while the PB (lf) is 2.45X, up 0.08X week-on-week [3] - The "Thousand-Year Herbal" initiative aims to establish a comprehensive communication system for the entire lifecycle of Chinese medicine, focusing on resource protection, quality control, and technological innovation [5] - The recent implementation of centralized procurement for Chinese medicine pieces is expected to drive industry standardization and enhance competitive advantages for companies with strong management and innovation capabilities [6] Market Performance - The Chinese medicine II index closed at 6845.97 points, reflecting a 3.12% increase, while the chemical pharmaceuticals index rose by 5.01% [2][14] - The performance of leading companies includes Qizheng Tibetan Medicine and Zhongsheng Pharmaceutical, while companies like Qidi Pharmaceutical and Kangmei Pharmaceutical lagged behind [2] Valuation - The Chinese medicine sector's PE (ttm) is at 29.58X, which is at the 35.13% percentile since 2013, while the PB (lf) is at 2.45X, at the 8.52% percentile since 2013 [3] Supply Chain Insights - The market for Chinese medicinal materials is currently balanced, with the price index remaining stable despite fluctuations in supply due to extreme weather [4] Investment Suggestions - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Companies with strong R&D capabilities and unique products are recommended, along with those less affected by centralized procurement [12]

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]

2025 年 7 月 28 日，启迪药业集团股份公司（以下简称"公司"） 收到公司 控股股东启迪科技服务有限公司（以下简称"启迪科服"）之一致行动人北京华 清投资有限公司（以下简称"华清投资"）股权解除质押的通知。 根据中国证券登记结算有限责任公司深圳分公司于 2025 年 7 月 28 日出具 的《投资者证券冻结信息》，华清投资已将质押给华龙证券股份有限公司的 2,270,000 股于 2025 年 7 月 25 日解除质押。（前次质押情况详见 2024 年 7 月 27 日刊登于《中国证券报》《证券时报》《上海证券报》和巨潮资讯网上的《关于控 股股东之一致行动人部分股权被质押的公告》，公告编号 2024-033） 证券代码：000590 证券简称：启迪药业 公告编号：2025-025 启迪药业集团股份公司 关于启迪科服之一致行动人部分股权解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 截至本公告日，华清投资持有公司 4,544,451 股，占公司总股本的 1.90%。本次解除质押股份 2,270,000 股后，华清投资持有的公司股份处于无质 ...

Core Viewpoint - A dramatic competition is unfolding in the capital market as Hunan Sailoxian Management Consulting Partnership successfully acquired a 24.47% stake in Qidi Pharmaceutical for 1.007 billion yuan, positioning itself as a potential new controlling shareholder [1][4][15] Group 1: Auction Details - The auction attracted eight bidders and garnered over 410,000 online viewers, with the bidding process extending to 138 rounds and 107 delays [5][6] - The starting price for the shares was approximately 450 million yuan, and the final bid represented a 124% premium over the starting price [7] - The auction price per share was about 17.19 yuan, while the closing price on the day of the auction was 13.86 yuan, indicating a significant price discrepancy [7] Group 2: Market Reactions - Following the auction, Qidi Pharmaceutical's stock experienced volatility, with a cumulative increase of 24.86% from July 9 to July 14, but a drop of 1.88% on July 15 [7][8] - The stock was listed on the Shenzhen Stock Exchange's "Dragon and Tiger List" due to its significant price fluctuations, with a notable sell-off from a specific brokerage [8][9] Group 3: Legal Context - The acquisition is set against a backdrop of a trademark infringement lawsuit initiated by Qidi Pharmaceutical against Hunan Hengchang Pharmaceutical, which is also linked to Hunan Sailoxian [10][11] - The lawsuit stems from allegations that Hengchang Pharmaceutical used Qidi's registered trademarks at a trade fair, leading to significant reputational damage for Qidi [10][11] Group 4: Financial Performance - Qidi Pharmaceutical has faced financial challenges, reporting a net loss of 125 million yuan in 2024 and an expected loss of 15 to 19 million yuan for the first half of the year [12] - The company's revenue has declined due to market conditions and rising material costs, impacting its overall profitability [12] Group 5: Future Implications - The potential acquisition raises questions about future asset injections and the strategic direction of Qidi Pharmaceutical under Hunan Sailoxian's control [16] - The relationship between Hunan Sailoxian and Hengchang Pharmaceutical may influence the resolution of ongoing legal disputes and the future operational strategy of Qidi Pharmaceutical [11][16]

Market Performance - As of July 21, the Shanghai Composite Index rose by 0.72%, closing at 3559.7912 points [1] - The Shenzhen Component Index increased by 0.86%, closing at 11007.487 points [1] Top Gainers in Hunan Stocks - Boyun New Materials opened at 7.910 and closed at 8.700, with a daily increase of 9.99% and a trading volume of 913,006 shares [2] - Yipuli opened at 14.100 and closed at 14.100, with a daily increase of 9.98% and a trading volume of 73,411 shares [2] - Shanhe Intelligent opened at 8.310 and closed at 8.820, with a daily increase of 9.98% and a trading volume of 967,465 shares [2] - Zhejiang Construction Investment opened at 9.210 and closed at 9.620, with a daily increase of 6.65% and a trading volume of 798,714 shares [2] - Changgao Electric New opened at 7.450 and closed at 7.680, with a daily increase of 6.37% and a trading volume of 779,409 shares [2] Top Losers in Hunan Stocks - Hengli Retreat opened at 0.160 and closed at 0.150, with a daily decrease of 11.76% and a trading volume of 611,606 shares [3] - Qidi Pharmaceutical opened at 12.430 and closed at 12.120, with a daily decrease of 2.96% and a trading volume of 173,563 shares [3] - Yueyang Xingchang opened at 18.080 and closed at 17.610, with a daily decrease of 2.87% and a trading volume of 122,456 shares [3] - ST Jiajia opened at 6.180 and closed at 6.060, with a daily decrease of 1.78% and a trading volume of 73,498 shares [3] - ST Jingfeng opened at 5.830 and closed at 5.760, with a daily decrease of 1.37% and a trading volume of 119,258 shares [3]

Core Viewpoint - The judicial auction of 58.607 million shares of Tsinghua Unigroup (启迪药业) has resulted in a significant change in the company's control, with Hunan Sailoxian Management Consulting Partnership winning the bid at 1.007 billion yuan, potentially altering the ownership structure of the company [2][3][4]. Group 1: Auction Details - The auction attracted over 400,000 online viewers and involved eight competitive buyers, culminating in 138 rounds of bidding and 107 extensions [2][3]. - Hunan Sailoxian, established on June 19, 2025, with a registered capital of 400 million yuan, won the auction, with its major shareholder being Jiang Xin, who also leads Hunan Hengchang Pharmaceutical [3]. Group 2: Ownership Changes - If the auction is finalized, Tsinghua Unigroup will completely exit its shareholder position, reducing its voting rights from 26.37% to 1.90%, while Hunan Sailoxian will become the largest shareholder with a 24.47% stake [3][4]. - The second-largest shareholder, Hengyang Hongxiang State Investment Group, holds 19.11% of the shares, indicating a close competition between state-owned and private entities [4]. Group 3: Legal Context - The auction stems from a financial dispute between Tsinghua Unigroup and the Agricultural Bank of China, leading to the shares being put up as collateral [2][3]. - Tsinghua Unigroup has previously engaged in legal action against Hengchang Pharmaceutical for trademark infringement, raising questions about future legal strategies post-control change [5].